NCT05694728View on ClinicalTrials.gov

A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine

PHASE2CompletedINTERVENTIONAL
Enrollment

780

Participants

Timeline

Start Date

May 23, 2020

Primary Completion Date

December 11, 2020

Study Completion Date

January 27, 2021

Conditions
Human Papilloma Virus Infection
Interventions
BIOLOGICAL

Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli)

"For Mid-dosage group, a 3-dose regimen administered at months 0, 2 and 6.~For High-dosage group, a 3-dose regimen administered at months 0, 2 and 6."

BIOLOGICAL

Recombinant Quadrivalent Human Papillomavirus (Types 6,11,16,18) Vaccine (Saccharomyces cerevisiae)

A 3-dose regimen administered at months 0, 2 and 6.

Trial Locations (1)

210009

CDC, Jiangsu Province, Nanjing

Sponsors
All Listed Sponsors
collaborator

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

collaborator

National Institutes for Food and Drug Control, China

OTHER

collaborator

Nanjing Sangruisi pharmtech Ltd.

UNKNOWN

collaborator

Shanghai Canming pharmtech Ltd.

UNKNOWN

lead

Beijing Health Guard Biotechnology, Inc

INDUSTRY